title: [The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML].
abstract: OBJECTIVE
  To compare the efficacy of high-dose cytarabine (HD-Ara-C) based chemotherapy for post-remission treatment in patients with t(8;21) (q22;q22) AML-M2 and those with normal karyotype AML-M2.
  
  
  METHODS
  AML-M2 patients were grouped into with (21 cases) or without (23 cases) t(8;21) (q22;q22) karyotype groups. After achieved remission by induction therapy, all patients received four cycles of HD-Ara-C (3 mg/m2 per 12 hours by three-hour infusion day 1 to day 3) with either mitoxantrone (7 mg m(-2) d(-1)) or aclarubicin (30 mg m(-2) d(-1)) or etoposide (70 mg m(-2) d(-1)) for 3d as post-remission treatment.
  
  
  RESULTS
  Relapse rate in the t(8;21) and the normal karyotype groups was 29% and 57% respectively (P<0.05); 3 year disease-free survival (DFS) rate was 71% and 43% respectively (P < 0.05). and 3 year over-all survival (OS) rate was 76% and 65% respectively (P >0.05).
  
  
  CONCLUSIONS
  Four cycles of high-dose cytarabine based combination chemotherapy as post-remission treatment improves long-term disease-free survival in patients with t(8;21) (q22;q22) AML-M2.
authors.affiliation: Department of Hematology, Henan Cancer Hospital, Henan Institute of Hematology, Zhengzhou 450008, China.
authors.forename: Hong-Yi
authors.initials: HY
authors.lastname: Li
authors.forename: Han
authors.initials: H
authors.lastname: Yue
authors.forename: Xu-Dong
authors.initials: XD
authors.lastname: Wei
authors.forename: Xing-Hu
authors.initials: XH
authors.lastname: Zhu
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Zhang
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Zhang
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Liu
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Bai-Jun
authors.initials: BJ
authors.lastname: Fang
authors.forename: Yu-Fu
authors.initials: YF
authors.lastname: Li
authors.forename: Yong-Ping
authors.initials: YP
authors.lastname: Song
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003561:Cytarabine